Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Etoposide in Pancreatic Cancer
NCT00202800Phase 2Completed
- Sponsor
- Corewell Health
- Start
- Mar 2002
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide in pancreatic cancer (PC), sponsored by Corewell Health. Primary endpoint: Response Rate. Started Mar 2002; status: completed.
02
Drugs
etoposide
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00202800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202800.